Celecoxib for treatment of nocturia caused by benign prostatic hyperplasia: a prospective, randomized, double-blind, placebo-controlled study.

@article{Falahatkar2008CelecoxibFT,
  title={Celecoxib for treatment of nocturia caused by benign prostatic hyperplasia: a prospective, randomized, double-blind, placebo-controlled study.},
  author={Siavash Falahatkar and Gholamreza Mokhtari and Farshid Pourreza and Seyed Alaeddin Asgari and Alireza Noshad Kamran},
  journal={Urology},
  year={2008},
  volume={72 4},
  pages={813-6}
}
OBJECTIVES Nocturia is a well-recognized symptom of benign prostatic hyperplasia (BPH), which is commonly treated by alpha(1)-blockers and/or 5alpha-reductase inhibitors. However, the effectiveness of these drugs for nocturia has been reported to be only 25%-39%. The aim of this study was to investigate the efficacy of celecoxib, a cyclooxygenase-2 inhibitor, in the treatment of patients with BPH complaining of nocturia. METHODS This was a prospective, randomized, double-blind, placebo… CONTINUE READING
21 Citations
22 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 21 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 22 references

Evaluation of the urologic patients: History, physical examination, and urinalysis

  • GS Gerber, CB Brendler
  • editors. Campbell-Walsh Urology, 9th ed
  • 2007
2 Excerpts

Prostatic hyperplasia: Etiology, pathophysiology, epidemiology and natural history

  • CG Roehborn, M John, D. Beign
  • editors. Campbell-Walsh Urology, 9th ed
  • 2007
1 Excerpt

hyperplasia is associated with focal upregulation of cyclooxygenase - 2 , Bcl - 2 and cell proliferation in glandular epithelium

  • TD Warner, JA Mitchell
  • 2004

Cyclooxygenase 2 and prostate carcinogenesis

  • K Dilger, C Herrlinger, J Peters
  • Cancer Lett
  • 2003

Similar Papers

Loading similar papers…